Mar 1, 2019 · RPS6 inhibition decreases NRF2 expression and restores sensitivity in HER2-amplified gastric cancer in vitro and in vivo. High NRF2 expression in gastric cancer patients predicts resistance to treatment. RPS6 and NRF2 inhibition could …

Mar 1, 2019 · We found RPS6 activation and NRF2 to be related to anti-HER2 drug resistance. RPS6 or NRF2 inhibition with siRNA reduced viability and resistance to anti-HER2 drugs. In knockdown cells for RPS6, a decrease of NRF2 expression was demonstrated, suggesting a potential link between these two proteins.

Mar 7, 2024 · PI3K/AKT/mTOR/ribosomal protein S6 (RPS6)/nuclear factor erythroid 2-related factor 2 (NRF2) axis. The PI3K/AKT/mTOR pathway is a key pathway for inducing resistance to trastuzumab. RPS6 is a common downstream effector of the PI3K/mTOR pathway, which activates NRF2.

Gambardella and coworkers found that NRF2 amplified the resistance to anti-HER2 drugs through the PI3K/AKT/mTOR/RPS6 pathway, and that ribosomal protein S6 (RPS6) inhibition decreased NRF2 expression and restored sensitivity in HER2-amplified gastric cancer.

NRF2 activation through RPS6 is related to resistance to both lapatinib and trastuzumab in . HER2. amplified gastric cancer models. Inhibition of RPS6 and NRF2. reduces cell viability . and tumor growth . in

To address whether RPS6 could be involved in NRF2 increase, a knockdown of RPS6 was performed. Western blot analysis highlighted the decrease of NRF2 expression in LR1OE silenced by RPS6...

In resistant cells, protein expression underlined the activation of PI3K pathway and of its downstream effector RPS6 protein. Analysing microarray, it was possible to identify, the activation of a large number of genes regulated by NFR2.

May 25, 2021 · Gambardella and coworkers found that NRF2 amplified the resistance to anti-HER2 drugs through the PI3K/AKT/mTOR/RPS6 pathway, and that ribosomal protein S6 (RPS6) inhibition decreased NRF2 expression and restored sensitivity in HER2-amplified gastric cancer.

Nov 30, 2018 · RPS6 inhibition decreases NRF2 expression and restores sensitivity in HER2-amplified gastric cancer in vitro and in vivo. High NRF2 expression in gastric cancer patients predicts resistance to treatment. RPS6 and NRF2 inhibition could …

Dec 7, 2018 · NRF2 through the PI3K/AKT/mTOR/RPS6 pathway could be a potential effector of resistance to anti-HER2 drugs in our models. RPS6 inhibition decreases NRF2 expression and restores sensitivity in HER2-amplified gastric cancer in vitro and in vivo.